Celgene (BUE:CELG) Cyclically Adjusted PB Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Celgene Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Celgene  (BUE:CELG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Celgene Cyclically Adjusted PB Ratio Related Terms


Celgene Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Celgene's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Cyclically Adjusted PB Ratio Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BUE:CELG vs GILD, BIIB, ACT: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Celgene's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celgene Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celgene's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celgene's Cyclically Adjusted PB Ratio falls into.



Celgene Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Celgene's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Celgene's adjusted Book Value per Share data for the three months ended in Sep. 2019 was:

Adj_Book=Book Value per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=950.207/256.7590*256.7590
=950.207

Current CPI (Sep. 2019) = 256.7590.

Celgene Quarterly Data

Book Value per Share CPI Adj_Book
200912 18.180 215.949 21.616
201003 20.046 217.631 23.650
201006 21.081 217.965 24.833
201009 22.152 218.439 26.038
201012 25.290 219.179 29.626
201103 25.702 223.467 29.531
201106 26.780 225.722 30.462
201109 26.458 226.889 29.941
201112 27.117 225.672 30.852
201203 30.234 229.392 33.841
201206 31.142 229.478 34.844
201209 31.733 231.407 35.210
201212 33.373 229.601 37.320
201303 33.790 232.773 37.272
201306 35.044 233.504 38.534
201309 40.981 234.149 44.938
201312 43.237 233.049 47.636
201403 44.404 236.293 48.250
201406 49.320 238.343 53.131
201409 60.690 238.031 65.465
201412 69.725 234.812 76.242
201503 75.048 236.119 81.608
201506 72.622 238.638 78.137
201509 64.205 237.945 69.282
201512 97.393 236.525 105.725
201603 95.666 238.132 103.149
201606 100.091 241.018 106.628
201609 108.698 241.428 115.600
201612 134.378 241.432 142.909
201703 150.893 243.801 158.913
201706 178.035 244.955 186.614
201709 219.294 246.819 228.126
201712 174.050 246.524 181.276
201803 142.345 249.554 146.455
201806 121.754 251.989 124.059
201809 255.892 252.439 260.271
201812 331.967 251.233 339.269
201903 454.367 254.202 458.937
201906 633.830 256.143 635.354
201909 950.207 256.759 950.207

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.